Physician profile
Alan D Haney
NPI 1700199981
$11,248.20
in general payments reported to CMS, 2019-2025
56 companies · $1,734 in 2025
The $1,734 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,368 · 2020: $896 · 2021: $1,472 · 2022: $1,606 · 2023: $2,047 · 2024: $2,125 · 2025: $1,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,906.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,530.59 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,340.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,140.15 | 2019-2025 | |
| Abbvie INC. | $1,075.51 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $612.90 | 2019-2025 | Jardiance, Ofev |
| Astrazeneca Pharmaceuticals Lp | $590.15 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $570.35 | 2019-2025 | Xifaxan |
| Amgen INC. | $438.31 | 2019-2024 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $425.56 | 2019-2025 | Spravato, Xarelto |
| Lilly USA, LLC | $303.35 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $268.53 | 2019-2024 | Verquvo, Belsomra, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $230.22 | 2019-2024 | Eliquis, Camzyos |
| Astellas Pharma US INC | $202.43 | 2019-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $168.06 | 2019-2022 | |
| Allergan, INC. | $167.42 | 2020 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Haney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.